Gender-affirming treatment impacts cholesterol levels

cholesterol
Credit: CC0 Public Domain

Gender-affirming hormone treatments caused cholesterol levels to increase for transfeminine individuals and to decrease for transmasculine individuals, according to a study published in JAMA Pediatrics.

Robert Garofalo, MD, MPH, the Potocsnak Family Professor in Adolescent & Young Adult Medicine, chief of Adolescent Medicine in the Department of Pediatrics and a professor of Preventive Medicine, was a co-author of the study.

Mortality and morbidity from differ between men and women. One hypothesized cause is sex-related differences in lipid profiles, according to the study.

Starting at puberty, male individuals have lower levels of high-density lipoprotein cholesterol (HDL-C) when compared to female individuals. However, the relative contribution of sex hormones versus sex chromosomes to this difference has remained unknown.

Two hundred sixty-nine transgender and gender-diverse adolescents were recruited into the multi-center study, of which one site was Ann & Robert Lurie Children's Hospital. Thirty percent of participants were transfeminine and 70 percent were transmasculine.

After six months of estradiol treatment in transfeminine participants, average HDL-C levels increased by about 27 percent to fall within the expected range for female adolescents. Conversely, for transmasculine individuals, six months of testosterone treatment led to average HDL-C dropping by about 18 percent, within the expected range for male adolescents.

The investigators found that obesity attenuated the benefit of estradiol treatment on HDL-C levels and exacerbated the association of testosterone treatment with outcomes after six months. These previously unknown findings should be taken into account when treating individuals, according to the authors.

Further, this study provides evidence that sex-related differences in cholesterol are primarily caused by differences in sex steroids, and these steroids work synergistically with other such as obesity.


Explore further

Gender-affirming hormone therapy may increase risk of high blood pressure

More information: Kate Millington et al. Association of High-Density Lipoprotein Cholesterol With Sex Steroid Treatment in Transgender and Gender-Diverse Youth, JAMA Pediatrics (2021). DOI: 10.1001/jamapediatrics.2020.5620
Journal information: JAMA Pediatrics

Citation: Gender-affirming treatment impacts cholesterol levels (2021, April 20) retrieved 9 May 2021 from https://medicalxpress.com/news/2021-04-gender-affirming-treatment-impacts-cholesterol.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
6 shares

Feedback to editors

User comments